Planta Med 2000; 66(6): 516-520
DOI: 10.1055/s-2000-8653
Original Paper
Georg Thieme Verlag Stuttgart · New York

Intravenous Pretreatment with Magnolol Protects Myocardium Against Stunning

Cheng-Hsiung Huang1,4 , Chuang-Ye Hong2,4 , Shen-Kou Tsai3,4,*, Shiau-Ting Lai1 , Zen-Chung Weng1 , Chun-Lien Chih1 , Y-Houng Hsieh1
  • 1 Department of Surgery, Veterans General Hospital, Taipei, Taiwan, R.O.C.
  • 2 Department of Medicine, Veterans General Hospital, Taipei, Taiwan, R.O.C.
  • 3 Department of Anesthesiology, College of Medicine, Taiwan University Hospital, Taipei, Taiwan, R.O.C.
  • 4 Institute of Clinical Medicine, Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Zoom Image

Abstract

Magnolol, an antioxidant, has been reported to possess various protective effects on the cardiovascular system. However, its effect on myocardial stunning has not been elucidated. The purpose of this study was to investigate the anti-stunning effect of magnolol by evaluating the recovery of regional myocardial function after 10-minute coronary artery occlusion in anesthetized, open-chest rabbits. There was no significant hemodynamic change after intravenous infusion of magnolol. Systolic wall thickening fraction (WThF) measured with an epicardial Doppler sensor in animals pretreated with normal saline and vehicle solution remained significantly depressed (60 ± 7 % and 77 ± 4 % of baseline WThF, respectively) 3 hours after coronary artery reperfusion (CAR). Pretreatment with magnolol (10-7 and 10-6 g/kg, intravenous infusion) significantly enhanced the recovery of systolic wall thickening fraction (98 ± 1 and 99 ± 1 % of baseline WThF, respectively) 60 minutes after CAR. This study demonstrated that intravenous pretreatment with magnolol protected myocardium against stunning.

Crossref Cited-by logo
Article Citations